Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 38 entries
Sorted by: Best Match Show Resources per page
Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract.

Therapeutic advances in medical oncology

Alese OB, El-Rayes BF, Sica G, Zhang G, Alexis D, La Rosa FG, Varella-Garcia M, Chen Z, Rossi MR, Adsay NV, Khuri FR, Owonikoko TK.
PMID: 25755678
Ther Adv Med Oncol. 2015 Mar;7(2):56-62. doi: 10.1177/1758834014567117.

OBJECTIVES: ALK-EML4 translocation is an established driver aberration in non-small cell lung cancer (NSCLC), with reported predilection for cases with signet ring histology. We assessed the presence of anaplastic lymphoma kinase (ALK) gene rearrangements in signet ring cancers arising...

Cite
Alese OB, El-Rayes BF, Sica G, et al. Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract. Ther Adv Med Oncol. 2015;7(2):56-62doi: 10.1177/1758834014567117.
Alese, O. B., El-Rayes, B. F., Sica, G., Zhang, G., Alexis, D., La Rosa, F. G., Varella-Garcia, M., Chen, Z., Rossi, M. R., Adsay, N. V., Khuri, F. R., & Owonikoko, T. K. (2015). Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract. Therapeutic advances in medical oncology, 7(2), 56-62. https://doi.org/10.1177/1758834014567117
Alese, Olatunji B, et al. "Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract." Therapeutic advances in medical oncology vol. 7,2 (2015): 56-62. doi: https://doi.org/10.1177/1758834014567117
Alese OB, El-Rayes BF, Sica G, Zhang G, Alexis D, La Rosa FG, Varella-Garcia M, Chen Z, Rossi MR, Adsay NV, Khuri FR, Owonikoko TK. Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract. Ther Adv Med Oncol. 2015 Mar;7(2):56-62. doi: 10.1177/1758834014567117. PMID: 25755678; PMCID: PMC4346214.
Copy Download .nbib Format: NLM
Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy.

Frontiers in oncology

Nazha B, Inal C, Owonikoko TK.
PMID: 32733795
Front Oncol. 2020 Jul 07;10:1000. doi: 10.3389/fonc.2020.01000. eCollection 2020.

Gangliosides are carbohydrate-containing sphingolipids that are widely expressed in normal tissues, making most subtypes unsuitable as targets for cancer therapy. However, the disialoganglioside GD2 subtype has limited expression in normal tissues but is overexpressed across a wide range of...

Cite
Nazha B, Inal C, Owonikoko TK. Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy. Front Oncol. 2020;10:1000doi: 10.3389/fonc.2020.01000.
Nazha, B., Inal, C., & Owonikoko, T. K. (2020). Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy. Frontiers in oncology, 101000. https://doi.org/10.3389/fonc.2020.01000
Nazha, Bassel, et al. "Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy." Frontiers in oncology vol. 10 (2020): 1000. doi: https://doi.org/10.3389/fonc.2020.01000
Nazha B, Inal C, Owonikoko TK. Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy. Front Oncol. 2020 Jul 07;10:1000. doi: 10.3389/fonc.2020.01000. eCollection 2020. PMID: 32733795; PMCID: PMC7358363.
Copy Download .nbib Format: NLM
Erratum: GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.

Oncotarget

Koo J, Wang X, Owonikoko TK, Ramalingam SS, Khuri FR, Sun SY.
PMID: 33613851
Oncotarget. 2021 Feb 02;12(3):251-252. doi: 10.18632/oncotarget.27752. eCollection 2021 Feb 02.

[This corrects the article DOI: 10.18632/oncotarget.3291.].

Cite
Koo J, Wang X, Owonikoko TK, et al. Erratum: GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth. Oncotarget. 2021;12(3):251-252doi: 10.18632/oncotarget.27752.
Koo, J., Wang, X., Owonikoko, T. K., Ramalingam, S. S., Khuri, F. R., & Sun, S. Y. (2021). Erratum: GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth. Oncotarget, 12(3), 251-252. https://doi.org/10.18632/oncotarget.27752
Koo, Junghui, et al. "Erratum: GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth." Oncotarget vol. 12,3 (2021): 251-252. doi: https://doi.org/10.18632/oncotarget.27752
Koo J, Wang X, Owonikoko TK, Ramalingam SS, Khuri FR, Sun SY. Erratum: GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth. Oncotarget. 2021 Feb 02;12(3):251-252. doi: 10.18632/oncotarget.27752. eCollection 2021 Feb 02. PMID: 33613851; PMCID: PMC7869579.
Copy Download .nbib Format: NLM
Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G.

Clinical lung cancer

Owonikoko TK, Redman MW, Byers LA, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Al Baghdadi T, Lara P, Miao J, Kelly K, Ramalingam SS, Herbst RS, Papadimitrakopoulou V, Gandara DR.
PMID: 33583720
Clin Lung Cancer. 2021 May;22(3):187-194.e1. doi: 10.1016/j.cllc.2021.01.001. Epub 2021 Jan 10.

PURPOSE: This signal finding study (S1400G) was designed to evaluate the efficacy of talazoparib in advanced stage squamous cell lung cancer harboring homologous recombination repair deficiency.PATIENTS AND METHODS: The full eligible population (FEP) had tumors with a deleterious mutation...

Cite
Owonikoko TK, Redman MW, Byers LA, et al. Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. Clin Lung Cancer. 2021;22(3):187-194.e1doi: 10.1016/j.cllc.2021.01.001.
Owonikoko, T. K., Redman, M. W., Byers, L. A., Hirsch, F. R., Mack, P. C., Schwartz, L. H., Bradley, J. D., Stinchcombe, T. E., Leighl, N. B., Al Baghdadi, T., Lara, P., Miao, J., Kelly, K., Ramalingam, S. S., Herbst, R. S., Papadimitrakopoulou, V., & Gandara, D. R. (2021). Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. Clinical lung cancer, 22(3), 187-194.e1. https://doi.org/10.1016/j.cllc.2021.01.001
Owonikoko, Taofeek K, et al. "Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G." Clinical lung cancer vol. 22,3 (2021): 187-194.e1. doi: https://doi.org/10.1016/j.cllc.2021.01.001
Owonikoko TK, Redman MW, Byers LA, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Al Baghdadi T, Lara P, Miao J, Kelly K, Ramalingam SS, Herbst RS, Papadimitrakopoulou V, Gandara DR. Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. Clin Lung Cancer. 2021 May;22(3):187-194.e1. doi: 10.1016/j.cllc.2021.01.001. Epub 2021 Jan 10. PMID: 33583720; PMCID: PMC8637652.
Copy Download .nbib Format: NLM
Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib.

Oncogene

Chen Z, Yu D, Owonikoko TK, Ramalingam SS, Sun SY.
PMID: 34635799
Oncogene. 2021 Dec;40(49):6653-6665. doi: 10.1038/s41388-021-02057-0. Epub 2021 Oct 11.

Emergence of acquired resistance to osimertinib (AZD9291), the first-approved third-generation EGFR inhibitor that selectively and irreversibly inhibits the activating EGFR mutations and the resistant T790M mutation, is a giant and urgent clinical challenge. Fully understanding the biology underlying the...

Cite
Chen Z, Yu D, Owonikoko TK, et al. Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib. Oncogene. 2021;40(49):6653-6665doi: 10.1038/s41388-021-02057-0.
Chen, Z., Yu, D., Owonikoko, T. K., Ramalingam, S. S., & Sun, S. Y. (2021). Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib. Oncogene, 40(49), 6653-6665. https://doi.org/10.1038/s41388-021-02057-0
Chen, Zhen, et al. "Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib." Oncogene vol. 40,49 (2021): 6653-6665. doi: https://doi.org/10.1038/s41388-021-02057-0
Chen Z, Yu D, Owonikoko TK, Ramalingam SS, Sun SY. Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib. Oncogene. 2021 Dec;40(49):6653-6665. doi: 10.1038/s41388-021-02057-0. Epub 2021 Oct 11. PMID: 34635799.
Copy Download .nbib Format: NLM
Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib.

Oncogene

Chen Z, Yu D, Owonikoko TK, Ramalingam SS, Sun SY.
PMID: 34635799
Oncogene. 2021 Dec;40(49):6653-6665. doi: 10.1038/s41388-021-02057-0. Epub 2021 Oct 11.

Emergence of acquired resistance to osimertinib (AZD9291), the first-approved third-generation EGFR inhibitor that selectively and irreversibly inhibits the activating EGFR mutations and the resistant T790M mutation, is a giant and urgent clinical challenge. Fully understanding the biology underlying the...

Cite
Chen Z, Yu D, Owonikoko TK, et al. Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib. Oncogene. 2021;40(49):6653-6665doi: 10.1038/s41388-021-02057-0.
Chen, Z., Yu, D., Owonikoko, T. K., Ramalingam, S. S., & Sun, S. Y. (2021). Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib. Oncogene, 40(49), 6653-6665. https://doi.org/10.1038/s41388-021-02057-0
Chen, Zhen, et al. "Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib." Oncogene vol. 40,49 (2021): 6653-6665. doi: https://doi.org/10.1038/s41388-021-02057-0
Chen Z, Yu D, Owonikoko TK, Ramalingam SS, Sun SY. Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib. Oncogene. 2021 Dec;40(49):6653-6665. doi: 10.1038/s41388-021-02057-0. Epub 2021 Oct 11. PMID: 34635799; PMCID: PMC8671366.
Copy Download .nbib Format: NLM
Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors.

Molecular cancer research : MCR

Qian G, Guo J, Vallega KA, Hu C, Chen Z, Deng Y, Wang Q, Fan S, Ramalingam SS, Owonikoko TK, Wei W, Sun SY.
PMID: 34183449
Mol Cancer Res. 2021 Oct;19(10):1622-1634. doi: 10.1158/1541-7786.MCR-21-0147. Epub 2021 Jun 28.

Expression of programmed death-ligand 1 (PD-L1) on cancer cells is a critical mechanism contributing to immunosuppression and immune escape. PD-L1 expression may also affect therapeutic outcomes of epidermal growth factor receptor (EGFR)-targeted therapy (e.g., with osimertinib/AZD9291) against EGFR-mutant non-small...

Cite
Qian G, Guo J, Vallega KA, et al. Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors. Mol Cancer Res. 2021;19(10):1622-1634doi: 10.1158/1541-7786.MCR-21-0147.
Qian, G., Guo, J., Vallega, K. A., Hu, C., Chen, Z., Deng, Y., Wang, Q., Fan, S., Ramalingam, S. S., Owonikoko, T. K., Wei, W., & Sun, S. Y. (2021). Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors. Molecular cancer research : MCR, 19(10), 1622-1634. https://doi.org/10.1158/1541-7786.MCR-21-0147
Qian, Guoqing, et al. "Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors." Molecular cancer research : MCR vol. 19,10 (2021): 1622-1634. doi: https://doi.org/10.1158/1541-7786.MCR-21-0147
Qian G, Guo J, Vallega KA, Hu C, Chen Z, Deng Y, Wang Q, Fan S, Ramalingam SS, Owonikoko TK, Wei W, Sun SY. Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors. Mol Cancer Res. 2021 Oct;19(10):1622-1634. doi: 10.1158/1541-7786.MCR-21-0147. Epub 2021 Jun 28. PMID: 34183449; PMCID: PMC8492505.
Copy Download .nbib Format: NLM
Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib.

Oncogene

Chen Z, Yu D, Owonikoko TK, Ramalingam SS, Sun SY.
PMID: 34635799
Oncogene. 2021 Dec;40(49):6653-6665. doi: 10.1038/s41388-021-02057-0. Epub 2021 Oct 11.

Emergence of acquired resistance to osimertinib (AZD9291), the first-approved third-generation EGFR inhibitor that selectively and irreversibly inhibits the activating EGFR mutations and the resistant T790M mutation, is a giant and urgent clinical challenge. Fully understanding the biology underlying the...

Cite
Chen Z, Yu D, Owonikoko TK, et al. Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib. Oncogene. 2021;40(49):6653-6665doi: 10.1038/s41388-021-02057-0.
Chen, Z., Yu, D., Owonikoko, T. K., Ramalingam, S. S., & Sun, S. Y. (2021). Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib. Oncogene, 40(49), 6653-6665. https://doi.org/10.1038/s41388-021-02057-0
Chen, Zhen, et al. "Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib." Oncogene vol. 40,49 (2021): 6653-6665. doi: https://doi.org/10.1038/s41388-021-02057-0
Chen Z, Yu D, Owonikoko TK, Ramalingam SS, Sun SY. Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib. Oncogene. 2021 Dec;40(49):6653-6665. doi: 10.1038/s41388-021-02057-0. Epub 2021 Oct 11. PMID: 34635799.
Copy Download .nbib Format: NLM
"What a man can do, a woman can do better": women farmers, livelihood and drug abuse in Adamawa State, northeastern Nigeria.

Journal of ethnicity in substance abuse

Owonikoko SB, Suleiman JBA, Maibaka WK, Tasiu N.
PMID: 33511921
J Ethn Subst Abuse. 2021 Jan 29;1-26. doi: 10.1080/15332640.2021.1871694. Epub 2021 Jan 29.

Drug and substance abuse among female population is on the rise but yet to be given adequate scholarly attention. This study examines how women farmers in Adamawa State are engaging in drug and substance abuse to enhance their farming...

Cite
Owonikoko SB, Suleiman JBA, Maibaka WK, et al. "What a man can do, a woman can do better": women farmers, livelihood and drug abuse in Adamawa State, northeastern Nigeria. J Ethn Subst Abuse. 2021;1-26doi: 10.1080/15332640.2021.1871694.
Owonikoko, S. B., Suleiman, J. B. A., Maibaka, W. K., & Tasiu, N. (2021). "What a man can do, a woman can do better": women farmers, livelihood and drug abuse in Adamawa State, northeastern Nigeria. Journal of ethnicity in substance abuse, 1-26. https://doi.org/10.1080/15332640.2021.1871694
Owonikoko, Saheed B, et al. ""What a man can do, a woman can do better": women farmers, livelihood and drug abuse in Adamawa State, northeastern Nigeria." Journal of ethnicity in substance abuse vol. (2021): 1-26. doi: https://doi.org/10.1080/15332640.2021.1871694
Owonikoko SB, Suleiman JBA, Maibaka WK, Tasiu N. "What a man can do, a woman can do better": women farmers, livelihood and drug abuse in Adamawa State, northeastern Nigeria. J Ethn Subst Abuse. 2021 Jan 29;1-26. doi: 10.1080/15332640.2021.1871694. Epub 2021 Jan 29. PMID: 33511921.
Copy Download .nbib Format: NLM
The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated MET.

American journal of cancer research

Yu D, Li Y, Sun KD, Gu J, Chen Z, Owonikoko TK, Ramalingam SS, Sun SY.
PMID: 33163272
Am J Cancer Res. 2020 Oct 01;10(10):3316-3327. eCollection 2020.

HQP8361 (MK8033) is a novel and selective MET kinase inhibitor that has completed a phase I clinical trial. AZD9291 (osimertinib) represents the first-approved third generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) for the treatment of non-small cell lung cancer (NSCLC) with...

Cite
Yu D, Li Y, Sun KD, et al. The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated MET. Am J Cancer Res. 2020;10(10):3316-3327
Yu, D., Li, Y., Sun, K. D., Gu, J., Chen, Z., Owonikoko, T. K., Ramalingam, S. S., & Sun, S. Y. (2020). The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated MET. American journal of cancer research, 10(10), 3316-3327.
Yu, Danlei, et al. "The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated MET." American journal of cancer research vol. 10,10 (2020): 3316-3327.
Yu D, Li Y, Sun KD, Gu J, Chen Z, Owonikoko TK, Ramalingam SS, Sun SY. The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated MET. Am J Cancer Res. 2020 Oct 01;10(10):3316-3327. eCollection 2020. PMID: 33163272; PMCID: PMC7642664.
Copy Download .nbib Format: NLM
Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung Cancer.

Clinical and translational science

Goldman JW, Barve M, Patel JD, Wozniak A, Dowlati A, Starodub A, Owonikoko TK, Edenfield W, Laurie SA, Da Costa D, Lally S, Koch M, Kosloski MP, Hoffman D, Dy GK.
PMID: 33340277
Clin Transl Sci. 2021 Mar;14(2):664-670. doi: 10.1111/cts.12928. Epub 2020 Dec 19.

Small cell lung cancer (SCLC) is a leading cause of cancer death worldwide, with few treatment options. Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate that targets delta-like 3 on SCLC cells to deliver a cytotoxic payload directly to tumor...

Cite
Goldman JW, Barve M, Patel JD, et al. Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung Cancer. Clin Transl Sci. 2020;14(2):664-670doi: 10.1111/cts.12928.
Goldman, J. W., Barve, M., Patel, J. D., Wozniak, A., Dowlati, A., Starodub, A., Owonikoko, T. K., Edenfield, W., Laurie, S. A., Da Costa, D., Lally, S., Koch, M., Kosloski, M. P., Hoffman, D., & Dy, G. K. (2021). Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung Cancer. Clinical and translational science, 14(2), 664-670. https://doi.org/10.1111/cts.12928
Goldman, Jonathan W, et al. "Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung Cancer." Clinical and translational science vol. 14,2 (2021): 664-670. doi: https://doi.org/10.1111/cts.12928
Goldman JW, Barve M, Patel JD, Wozniak A, Dowlati A, Starodub A, Owonikoko TK, Edenfield W, Laurie SA, Da Costa D, Lally S, Koch M, Kosloski MP, Hoffman D, Dy GK. Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung Cancer. Clin Transl Sci. 2021 Mar;14(2):664-670. doi: 10.1111/cts.12928. Epub 2020 Dec 19. PMID: 33340277; PMCID: PMC7993269.
Copy Download .nbib Format: NLM
Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study.

Clinical cancer research : an official journal of the American Association for Cancer Research

Byers LA, Bentsion D, Gans S, Penkov K, Son C, Sibille A, Owonikoko TK, Groen HJM, Gay CM, Fujimoto J, de Groot P, Dunbar M, Kang K, He L, Sehgal V, Glasgow J, Bach BA, Ellis PM.
PMID: 33947690
Clin Cancer Res. 2021 Jul 15;27(14):3884-3895. doi: 10.1158/1078-0432.CCR-20-4259. Epub 2021 May 04.

PURPOSE: This study investigated the efficacy and safety of oral PARP inhibitor veliparib, plus carboplatin and etoposide in patients with treatment-naïve, extensive-stage small cell lung cancer (ED-SCLC).PATIENTS AND METHODS: Patients were randomized 1:1:1 to veliparib [240 mg twice daily...

Cite
Byers LA, Bentsion D, Gans S, et al. Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study. Clin Cancer Res. 2021;27(14):3884-3895doi: 10.1158/1078-0432.CCR-20-4259.
Byers, L. A., Bentsion, D., Gans, S., Penkov, K., Son, C., Sibille, A., Owonikoko, T. K., Groen, H. J. M., Gay, C. M., Fujimoto, J., de Groot, P., Dunbar, M., Kang, K., He, L., Sehgal, V., Glasgow, J., Bach, B. A., & Ellis, P. M. (2021). Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(14), 3884-3895. https://doi.org/10.1158/1078-0432.CCR-20-4259
Byers, Lauren Averett, et al. "Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,14 (2021): 3884-3895. doi: https://doi.org/10.1158/1078-0432.CCR-20-4259
Byers LA, Bentsion D, Gans S, Penkov K, Son C, Sibille A, Owonikoko TK, Groen HJM, Gay CM, Fujimoto J, de Groot P, Dunbar M, Kang K, He L, Sehgal V, Glasgow J, Bach BA, Ellis PM. Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study. Clin Cancer Res. 2021 Jul 15;27(14):3884-3895. doi: 10.1158/1078-0432.CCR-20-4259. Epub 2021 May 04. PMID: 33947690.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 38 entries